FDA and HHS should im­prove in­sti­tu­tion­al re­view board in­spec­tion prac­tices, GAO says

The US Gov­ern­ment Ac­count­abil­i­ty Of­fice has made four rec­om­men­da­tions to the FDA and HHS to im­prove their over­sight of in­sti­tu­tion­al re­view boards’ (IRBs) own in­spec­tions of re­search stud­ies, ac­cord­ing to a new re­port.

IRBs are meant to keep a sharp eye on the ethics and safe­ty of re­search stud­ies in­volv­ing hu­man pa­tients, from be­hav­ioral stud­ies to clin­i­cal tri­als, in­clud­ing over­see­ing over­all con­duct and main­tain­ing da­ta in­tegri­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER